Plain-English translation of NCT06751914 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a personalized combined with standard second-line chemotherapy for colorectal cancer patients whose disease has progressed after initial treatment. The vaccine is custom-made for each patient using their own tumor genetic information to help their immune system recognize and fight cancer cells. You would receive the vaccine through 10 injections over 21 weeks, alongside conventional chemotherapy.
Colorectal cancer often comes back or stops responding to first-line treatment, and patients need better options. This trial explores whether training your own immune system to recognize your specific tumor—using a personalized vaccine—might help when combined with standard chemotherapy.
You likely qualify if…
You likely don't qualify if…
Over 21 weeks, you would receive standard chemotherapy and 10 vaccine injections under the skin. Before treatment starts, doctors will take blood samples and perform genetic testing to design your personalized vaccine. After the initial 21-week treatment period, you will have follow-up visits every 6 weeks that include blood tests, physical exams, CT or MRI scans, and other necessary tests to monitor how well the treatment is working.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China